Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 13 | 2024 | 414 | 2.910 |
Why?
|
| Dermatology | 7 | 2025 | 74 | 2.200 |
Why?
|
| Skin Diseases | 3 | 2025 | 83 | 1.680 |
Why?
|
| Psoriasis | 5 | 2020 | 55 | 1.330 |
Why?
|
| Neurofibromatosis 1 | 2 | 2023 | 32 | 1.300 |
Why?
|
| Radiography | 3 | 2025 | 536 | 0.950 |
Why?
|
| Radiation Exposure | 1 | 2025 | 22 | 0.940 |
Why?
|
| Radiation Dosage | 1 | 2025 | 134 | 0.880 |
Why?
|
| Polyps | 1 | 2023 | 4 | 0.870 |
Why?
|
| Fibroma | 1 | 2023 | 13 | 0.870 |
Why?
|
| Pigmentation Disorders | 1 | 2023 | 9 | 0.820 |
Why?
|
| Down Syndrome | 2 | 2021 | 47 | 0.810 |
Why?
|
| Pediatrics | 1 | 2025 | 250 | 0.780 |
Why?
|
| Funnel Chest | 1 | 2021 | 7 | 0.750 |
Why?
|
| Cafe-au-Lait Spots | 2 | 2023 | 7 | 0.730 |
Why?
|
| Skin | 3 | 2021 | 377 | 0.720 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2020 | 9 | 0.710 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2020 | 4 | 0.710 |
Why?
|
| Skin Diseases, Vascular | 1 | 2020 | 3 | 0.690 |
Why?
|
| Mononeuropathies | 1 | 2020 | 5 | 0.690 |
Why?
|
| Skin Ulcer | 1 | 2020 | 15 | 0.680 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2020 | 12 | 0.670 |
Why?
|
| Nevus | 2 | 2022 | 22 | 0.650 |
Why?
|
| Nevus, Pigmented | 3 | 2024 | 19 | 0.620 |
Why?
|
| Child Abuse | 2 | 2017 | 90 | 0.540 |
Why?
|
| Melanoma | 5 | 2023 | 331 | 0.520 |
Why?
|
| Skin Pigmentation | 1 | 2016 | 33 | 0.510 |
Why?
|
| Diagnosis, Differential | 6 | 2021 | 964 | 0.480 |
Why?
|
| Adolescent | 11 | 2023 | 6172 | 0.470 |
Why?
|
| Fasciitis | 1 | 2014 | 2 | 0.460 |
Why?
|
| Humans | 34 | 2025 | 62682 | 0.450 |
Why?
|
| Scalp Dermatoses | 1 | 2014 | 4 | 0.450 |
Why?
|
| Nails | 2 | 2013 | 40 | 0.430 |
Why?
|
| Sarcoidosis | 1 | 2014 | 34 | 0.420 |
Why?
|
| Nails, Malformed | 1 | 2013 | 6 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 1589 | 0.410 |
Why?
|
| Infant | 7 | 2024 | 1602 | 0.410 |
Why?
|
| Melanosis | 2 | 2023 | 9 | 0.410 |
Why?
|
| Child | 8 | 2025 | 4444 | 0.360 |
Why?
|
| Male | 21 | 2024 | 29487 | 0.340 |
Why?
|
| Retrospective Studies | 8 | 2023 | 6533 | 0.320 |
Why?
|
| Female | 20 | 2024 | 32495 | 0.300 |
Why?
|
| Dermoscopy | 3 | 2016 | 13 | 0.270 |
Why?
|
| Methotrexate | 3 | 2020 | 80 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 2150 | 0.250 |
Why?
|
| Infant, Newborn | 5 | 2024 | 1341 | 0.250 |
Why?
|
| Child, Preschool | 4 | 2020 | 1937 | 0.240 |
Why?
|
| Etanercept | 2 | 2020 | 32 | 0.240 |
Why?
|
| Patch Tests | 2 | 2021 | 11 | 0.220 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2023 | 4 | 0.220 |
Why?
|
| Nose | 1 | 2024 | 31 | 0.220 |
Why?
|
| Dermatologic Agents | 2 | 2017 | 21 | 0.220 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1541 | 0.210 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2023 | 9 | 0.210 |
Why?
|
| Necrosis | 1 | 2024 | 143 | 0.210 |
Why?
|
| Mosaicism | 1 | 2023 | 29 | 0.210 |
Why?
|
| Lower Extremity | 1 | 2023 | 164 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 376 | 0.180 |
Why?
|
| Biopsy | 2 | 2020 | 430 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 109 | 0.180 |
Why?
|
| Tongue Diseases | 1 | 2020 | 4 | 0.180 |
Why?
|
| Conjunctivitis | 1 | 2020 | 5 | 0.180 |
Why?
|
| Hemangioma | 1 | 2020 | 28 | 0.170 |
Why?
|
| Exanthema | 1 | 2020 | 27 | 0.170 |
Why?
|
| Rituximab | 1 | 2020 | 83 | 0.170 |
Why?
|
| Biological Factors | 1 | 2020 | 21 | 0.170 |
Why?
|
| Postnatal Care | 1 | 2020 | 43 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2020 | 161 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 169 | 0.160 |
Why?
|
| Physical Examination | 2 | 2015 | 112 | 0.150 |
Why?
|
| Folliculitis | 1 | 2017 | 6 | 0.140 |
Why?
|
| Malassezia | 1 | 2017 | 6 | 0.140 |
Why?
|
| Facial Dermatoses | 1 | 2017 | 10 | 0.140 |
Why?
|
| Acne Vulgaris | 1 | 2017 | 24 | 0.140 |
Why?
|
| Biopsy, Needle | 2 | 2015 | 137 | 0.140 |
Why?
|
| Fractures, Multiple | 1 | 2017 | 2 | 0.140 |
Why?
|
| Menkes Kinky Hair Syndrome | 1 | 2017 | 3 | 0.140 |
Why?
|
| Students, Medical | 3 | 2015 | 255 | 0.140 |
Why?
|
| Sampling Studies | 1 | 2016 | 68 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 6 | 0.130 |
Why?
|
| Ophthalmology | 1 | 2016 | 24 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 33 | 0.130 |
Why?
|
| Propylene Glycol | 1 | 2015 | 3 | 0.120 |
Why?
|
| Histamine Antagonists | 1 | 2015 | 5 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 105 | 0.120 |
Why?
|
| Adult | 4 | 2020 | 16629 | 0.120 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2015 | 13 | 0.120 |
Why?
|
| Allergens | 1 | 2015 | 52 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2017 | 183 | 0.120 |
Why?
|
| Excipients | 1 | 2015 | 49 | 0.120 |
Why?
|
| Nevus, Spindle Cell | 1 | 2014 | 1 | 0.120 |
Why?
|
| Epithelioid Cells | 1 | 2014 | 4 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 612 | 0.110 |
Why?
|
| Shoulder | 1 | 2014 | 29 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 432 | 0.110 |
Why?
|
| Sarcoma | 1 | 2014 | 36 | 0.110 |
Why?
|
| Telangiectasis | 1 | 2014 | 4 | 0.110 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2014 | 14 | 0.110 |
Why?
|
| Alopecia | 1 | 2014 | 25 | 0.110 |
Why?
|
| Motion Pictures | 1 | 2013 | 11 | 0.110 |
Why?
|
| Melanocytes | 1 | 2014 | 80 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2014 | 142 | 0.100 |
Why?
|
| Child Development | 1 | 2013 | 83 | 0.100 |
Why?
|
| Education, Medical | 1 | 2013 | 182 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2013 | 203 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2015 | 713 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 315 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2018 | 787 | 0.080 |
Why?
|
| Dacryocystitis | 1 | 2009 | 3 | 0.080 |
Why?
|
| HLA-C Antigens | 1 | 2008 | 3 | 0.080 |
Why?
|
| Retinoids | 1 | 2008 | 12 | 0.080 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 23 | 0.070 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 31 | 0.070 |
Why?
|
| Interleukin-23 | 1 | 2008 | 18 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 63 | 0.070 |
Why?
|
| Causality | 1 | 2008 | 58 | 0.070 |
Why?
|
| Phototherapy | 1 | 2008 | 35 | 0.070 |
Why?
|
| Calcineurin | 1 | 2008 | 47 | 0.070 |
Why?
|
| Interleukin-12 | 1 | 2008 | 128 | 0.070 |
Why?
|
| Vitamins | 1 | 2008 | 81 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 786 | 0.070 |
Why?
|
| Vitamin D | 1 | 2008 | 139 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2008 | 188 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 463 | 0.060 |
Why?
|
| Comorbidity | 1 | 2008 | 1118 | 0.060 |
Why?
|
| Schools, Medical | 2 | 2015 | 145 | 0.050 |
Why?
|
| Pressure Ulcer | 1 | 2024 | 35 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 890 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 1345 | 0.050 |
Why?
|
| United States | 4 | 2020 | 7721 | 0.050 |
Why?
|
| Self Efficacy | 2 | 2014 | 202 | 0.050 |
Why?
|
| Melanins | 1 | 2022 | 24 | 0.050 |
Why?
|
| Aged | 2 | 2018 | 14254 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2540 | 0.050 |
Why?
|
| Tongue | 1 | 2020 | 15 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 3258 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 755 | 0.040 |
Why?
|
| Ketoconazole | 1 | 2017 | 8 | 0.040 |
Why?
|
| Fluconazole | 1 | 2017 | 13 | 0.040 |
Why?
|
| Torso | 1 | 2017 | 19 | 0.040 |
Why?
|
| Forehead | 1 | 2017 | 17 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 839 | 0.040 |
Why?
|
| Pruritus | 1 | 2017 | 30 | 0.040 |
Why?
|
| North America | 1 | 2017 | 111 | 0.040 |
Why?
|
| Folic Acid | 1 | 2017 | 41 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 194 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2017 | 126 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 804 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 2540 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4633 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 122 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 433 | 0.030 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2015 | 155 | 0.030 |
Why?
|
| Intention | 1 | 2014 | 69 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 126 | 0.030 |
Why?
|
| Brain | 1 | 2022 | 1550 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1344 | 0.030 |
Why?
|
| Scalp | 1 | 2013 | 29 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 502 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2013 | 252 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1159 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 585 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2445 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5303 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2040 | 0.020 |
Why?
|
| Middle Aged | 2 | 2018 | 17365 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 587 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1070 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3742 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5591 | 0.020 |
Why?
|